Biocon, BahiaFarma, Bionovis Ink MoU to Co-Develop Breast Cancer Therapy
The pact was signed for the development of Pertuzumab, indicated for HER-2 metastatic breast cancer.
New Delhi: BahiaFarma, Biocon Biologics Ltd, and Bionovis on Saturday inked a memorandum of understanding (MoU) for the development of a medicine.
The MoU was inked in the presence of visiting Brazilian President Luiz Inacio Lula da Silva and Commerce and Industry Minister Piyush Goyal at the Ficci's India-Brazil Business Forum.
The pact was signed for the development of Pertuzumab, indicated for HER-2 metastatic breast cancer.
Another MoU was signed between NMDC Ltd, Vale SA, and Adani Gangavaram Port Ltd to increase cooperation in creating a facility under a Special Economic Zone (SEZ) regime at the Port of Gangavaram, intended for blending and selling iron ore fines.
NMDC will supply low-grade ore, Vale will supply high-grade ore, and AGPL will be responsible for port infrastructure, blending area, unloading and loading operations, yard management, obtaining licenses, and carrying out blending in accordance with the technical requirements of the parties.
The MoU is valid for 12 months and renewable for an additional 12 months. The project is valued at about USD 500 million.
An MoU between Farmanguinhos/Fiocruz and Biocon Pharma Ltd was inked to set up R&D in strategic pharmaceutical ingredients and medicines for SUS, with emphasis on rare diseases, oncology, and immunosuppressants.
The cooperation also includes co-development of active pharmaceutical ingredients and finished products; sharing of technical, scientific, and regulatory knowledge; capacity building of human resources; exchange of specialists; technical and economic feasibility studies; and assessment of opportunities for production, regulatory registration, and supply of strategic medicines for public health systems, especially SUS.
ApexBrasil and the Federation of Indian Chambers of Commerce and Industry (FICCI) also signed a pact to enhance cooperation in trade, and foreign direct investments between the two countries.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.